文献速递生殖医学妇科

分娩后乳腺癌风险短暂升高:对生育治疗与代孕的启示

Transiently increased risk of breast cancer after childbirth: implications for fertility treatments and surrogacy.
PubMed 文献 · Hum Reprod · 2020-01-01

本文基于近期一项荟萃分析,指出分娩后二十余年内乳腺癌相对风险实际升高,且高龄初产、有家族史者风险更高,哺乳不降低风险。作者建议所有生育治疗的知情同意应告知每次妊娠会小幅增加短期乳腺癌风险,代孕因风险获益比不同尤需关注,并呼吁专业学会更新知情同意推荐。

要点

  • 分娩后二十余年内乳腺癌相对风险升高,而非既往认为的保护效应。
  • 高龄初产和有家族史者乳腺癌风险更高,哺乳不降低该风险。
  • 生育治疗知情同意应告知每次妊娠小幅增加短期乳腺癌风险。

核心结论

  • 近期荟萃分析报告分娩后二十余年内乳腺癌相对风险实际升高,直至相对风险转为负值。
  • 每次妊娠会小幅增加短期乳腺癌风险,代孕者的风险获益比与普通生育治疗显著不同。

研究设计与样本

  • 本文为基于近期一项荟萃分析结果的评论性文章,未报告原始研究设计与样本量。

主要发现

  • 荟萃分析报告分娩后二十余年内乳腺癌风险高于既往认知,之后相对风险才转为负值。
  • 高龄初产和有家族史的女性乳腺癌风险似乎更高。
  • 哺乳未降低乳腺癌风险。

临床怎么用

  • 所有生育治疗的知情同意应告知患者每次妊娠会小幅增加短期乳腺癌风险。
  • 代孕场景下风险获益比显著不同,知情同意信息尤需关注。
  • 专业学会宜更新生育治疗尤其是代孕的知情同意推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Whereas longstanding dogma has purported that pregnancies protect women from breast cancer, a recent meta-analysis now mandates reconsideration since it reported an actual higher breast cancer risk for more than two decades after childbirth before the relative risk turns negative. Moreover, the risk of breast cancer appears higher for women having their first birth at an older age and with a family history and it is not reduced by breastfeeding. The process of obtaining informed consent for all fertility treatments, therefore, must make patients aware of the facts that every pregnancy, to a small degree, will increase the short-term breast cancer risk. This observation may be even more relevant in cases of surrogacy where women agree to conceive without deriving benefits of offspring from assuming the risk, thus creating a substantially different risk-benefit ratio. Consequently, it appears prudent for professional societies in the field to update recommendations regarding consent information for all fertility treatments but especially for treatments involving surrogacy.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Blumenfeld Z, Gleicher N, Adashi EY, et al. Transiently increased risk of breast cancer after childbirth: implications for fertility treatments and surrogacy. Hum Reprod. 2020. PMID: 32472674. doi:10.1093/humrep/deaa102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。